One hundred and four‑week real‑world effectiveness of deucravacitinib 6 mg for genital, scalp, and nail psoriasis: A prospective study in Japan

Supplementary Table 1. Baseline characteristics of patients with psoriasis (n = 132) Supplementary Table 2. Transition of total Psoriasis Area and Severity Index (PASI), PASI on four anatomical sites, and Dermatology Life Quality Index (DLQI) scores in 132 patients with psoriasis during treatment with deucravacitinib 6 mg Supplementary Table 3. Week 16, 52, 104, 156, and 196 outcomes in the present study and published comparator values Supplementary Table 4. Treatment-emergent adverse events (TEAEs) until week 104 of deucravacitinib treatment in 132 patients with psoriasis Supplementary METHODS